** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86
** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago
** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago
** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer
** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025
** SNDX's shares have fallen 35% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。